BillionToOne Achieves Major Milestone with One Million UNITY Prenatal Tests

BillionToOne Celebrates One Million UNITY Tests

BillionToOne, a prominent name in the field of molecular diagnostics, has recently marked a significant achievement by conducting over one million UNITY prenatal tests. This milestone reflects the company's mission to make accurate and accessible diagnostic tests available to everyone.

Launched just five years ago, the UNITY test stands out as the only commercially available non-invasive prenatal screening that evaluates fetal risks for various aneuploidies, recessive conditions, and fetal antigens, all from just one maternal blood sample. This innovation has propelled BillionToOne to the forefront of the prenatal testing industry, showcasing their expertise in creating transformative healthcare solutions.

Key Technology Behind UNITY

The remarkable success of the UNITY Fetal Risk Screen™ can be attributed to BillionToOne's patented Quantitative Counting Template™ (QCT™) technology. This proprietary method allows for direct assessment of a fetus's risk for recessively inherited conditions—such as cystic fibrosis, spinal muscular atrophy, and sickle cell disease—without needing a sample from a male partner or resorting to invasive testing methods.

Oguzhan Atay, Ph.D., co-founder and CEO of BillionToOne, emphasized that reaching the milestone of one million tests is not only a significant achievement for the company but also demonstrates the profound impact of their technology on prenatal care. He noted that the current annual run-rate is already exceeding 500,000 tests, indicating remarkable growth and positioning UNITY as the new standard in prenatal diagnostics.

Growth in the Market

BillionToOne has also established itself as the fastest-growing molecular diagnostics laboratory, boasting an impressive 100% year-over-year revenue growth in 2024. This rapid expansion can be attributed to the company's commitment to democratizing access to vital prenatal testing, particularly for families who require such services the most. Moreover, BillionToOne's QCT technology plays a crucial role in their Northstar Select® and Northstar Response® assays, aiming to revolutionize cancer care by utilizing non-invasive blood tests for treatment selection and response monitoring.

Conclusion

The achievement of one million UNITY tests is a testament to BillionToOne’s dedication to improving prenatal care through innovative and accessible technologies. For more detailed information on the UNITY test and its benefits, individuals are encouraged to visit www.unityscreen.com.

In today’s landscape, where early and non-invasive testing can significantly influence health outcomes, BillionToOne is leading the way in ensuring that comprehensive and accurate diagnostics are within everyone's reach. By continuously pushing the boundaries of molecular diagnostics, the company is setting a new benchmark for quality and accessibility in healthcare.

BillionToOne is headquartered in Menlo Park, California, and is on a mission to make molecular diagnostics not just more accurate, but also efficient and accessible for all. For additional inquiries, please visit www.billiontoone.com.